[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506547":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":41,"responsibleParty":58,"collaborators":23,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":23,"enrollmentInfo":70,"targetDuration":23,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":83,"overallStatus":43,"whyStopped":23,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Rochester","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Telehealth Serious Illness Care Program","EXPERIMENTAL","The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).",[13],"Behavioral: Telehealth Serious Illness Care Program",{"label":15,"type":6,"description":16,"interventionNames":17},"Control","Education materials developed by the NCI on \"Communication in Cancer Care (PDQ®) - Patient Version\"",[18],"Other: Education Control",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"BEHAVIORAL",[9],null,{"type":6,"name":25,"description":16,"armGroupLabels":26,"otherNames":23},"Education Control",[15],[28],{"name":29,"affiliation":5,"role":30},"Kah Poh Loh","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},"Kah Poh Loh, MD","CONTACT","585-276-4353","Kahpoh_Loh@URMC.Rochester.edu",{"name":38,"role":34,"phone":39,"phoneExt":23,"email":40},"Becky Gravenstede","585-727-4728","becky_gravenstede@urmc.rochester.edu",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Rochester","New York","14642","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-77.61556,43.15478,{"lat":53,"lon":52},[56],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":57},"kahpoh_loh@urmc.rochester.edu",{"type":30,"investigatorFullName":29,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Associate Professor - Department of Medicine, Hematology\u002FOncology (SMD)","100506547","a-telehealth-advance-care-planning-intervention-100506547",false,"NCT05875805","A Telehealth Advance Care Planning Intervention","A Telehealth Advance Care Planning Intervention for Older Patients With Myeloid Malignancies: A Pilot Randomized Controlled Trial","SICP RCT","Inclusion and Exclusion Criteria for Patients\n\nInclusion criteria:\n\n* Age ≥60 years\n* A diagnosis of AML, MDS, and similar myeloid malignancies (including but not limited to MDS\u002FMPN overlap syndrome, myelofibrosis)\n* Being managed in the outpatient settings\n* Able to provide informed consent\n* English-speaking\n\nExclusion criteria:\n\n\\- None\n\nInclusion and Exclusion Criteria for Caregivers\n\nInclusion criteria:\n\n* Age ≥18 years\n* Selected by patient when asked if there is a \"family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters\"\n* Able to provide informed consent\n* English-speaking\n\nExclusion criteria:\n\n\\- None\n\nInclusion and Exclusion Criteria for Oncology Providers\n\nInclusion criteria:\n\n\\- Oncologists and\u002For APPs who will be conducting the telehealth-delivered ACP visit\n\nExclusion criteria:\n\n\\- None","ALL","60 Years",{"count":71,"type":72},207,"ESTIMATED","INTERVENTIONAL",[75],"NA","The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.",[78,79,80,81,82],"Myeloid Malignancy","Acute Myeloid Leukemia","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myelofibrosis",[84,85,86,87],"Older adults","Myeloid malignancies","Geriatric hematology","Serious illness conversations","2026-03-29",{"date":90,"type":91},"2026-04-03","ACTUAL",{"date":93,"type":91},"2024-05-20",{"date":95,"type":72},"2027-12-31",{"name":5,"class":6},1]